After the leaders of the NIH, FDA, and HHS made an announcement stating that both pregnant women and children were going to be taken off the COVID-19 immunization schedule, they decided to offer a new designation for the latter group, making it a shared decision between providers and patients.
At MAD-ID 2025, Kimberly Leuthner, PharmD, FIDSA, highlights the need for larger prospective studies amid limited current evidence.
The company's vaccine, mRNA-1283, becomes the first approval under the new federal guidelines.
At MAD-ID 2025, Jiye Park, PharmD, presents findings showing once-daily dosing is effective, with no added benefit from extended vancomycin use after antibiotics.
At MAD-ID 2025, Dakota Rorie, PharmD, highlights cost and access barriers to uptake of preferred CDI therapy.
At MAD-ID 2025, Rachel M. Kenney, PharmD, discusses treatment shifts, microbiome innovations, and pharmacists' roles in optimizing outcomes.
Despite the funding being terminated, the company said data from its phase 1/2 study of its investigational vaccine, mRNA-1018, demonstrated positive interim results.
Timmy Do, PharmD, BCIDP, BCPS, presents case series at MAD-ID 2025 on investigational therapies following tecovirimat failure.
At MAD-ID 2025, Cadhan McFadden presents data from a multidisciplinary ambulatory care project using PEN-FAST scoring and oral challenges to improve antibiotic access and accuracy.
A new study being presented at MAD-ID looked at this class of therapies vs oral penicillins and found the former to be non-inferior to the latter.
At MAD-ID 2025, Elizabeth Dodds Ashley, PharmD, MHS, explains how NHSN’s Antibiotic Resistance Option is shaping stewardship and clinical decision-making.
At MAD-ID, a study highlights how prescribing in these settings suggests a need for antimicrobial stewardship efforts.
At MAD-ID, Timothy Aungst, PharmD, outlines the role of artificial intelligence in clinical decision-making, curriculum design, and infectious disease practice.
If approved, Spero Therapeutics and GSK’s antibiotic, tebipenem HBr, could be the first oral carbapenem for US patients with complicated urinary tract infections (cUTIs).
The World Health Organization (WHO) says the previously predominant LP81 variant has been declining, and that the NB181 strain, which is a variant under monitoring, is increasing.
Ep 1, Part 2 of 4, insights from Robert Bransfield, MD's research on the immune system’s role in psychiatric disorders.
Following a positive safety review, Vaxart advances its needle-free, room-temperature stable oral vaccine candidate with government-backed funding and a year-long follow-up study.
In a joint announcement, the leaders of the NIH, HHS, and FDA, made comments about this CDC immunization removal.
Ep 1, Part 1 of 4: Robert Bransfield, MD, introduces his understanding of how infectious diseases may trigger or worsen psychiatric disorders through genetics, immune response, and environmental factors.
With this news, Sanofi's immunization becomes the only MenACWY vaccine that can help protect individuals 6 weeks of age and older, with no upper age limit.
TAXIS Pharmaceuticals announced it received a $2.9 million federal grant, which will allow the company to further advance its efforts with its dihydrofolate reductase inhibitors for the rapidly spreading and antibiotic-resistant strain of Neisseria gonorrhoeae.
A published study reveals how an extra gene allows a specific mycetoma-causing fungus to neutralize itraconazole when treating the neglected tropical disease.
A panel discusses how vaccine policy under new federal government policies, why misinformation has flourished and what individual providers can do to win back patient trust.
Innoviva launches ceftobiprole in the US, shifts in FDA COVID-19 vaccine policy, a surge in fungal infections, and more.
The FDA committee advisors are recommending the monovalent JN1-lineage-based COVID-19 vaccines preferentially using the LP81 strain.
Paul Feuerstadt, MD, discuses the treatment’s overall safety and efficacy profile and provides insights on data around smaller subsets of patients with comorbidities.
The state reported 3123 cases, a significant jump from 2024's 1011 cases in the same period, with experts citing environmental factors.
Pediatrician Sharon Nachman, MD, discusses the potential effects of the new policy including how things like vaccine access, incidence rates, and participation in placebo-controlled trials may change.
The company made the decision after the FDA requested more vaccine data for the mRNA-1083 vaccine. Moderna plans to resubmit their Biologics License Application (BLA) for the vaccine later this year.
FDA leadership says they expect more testing for COVID-19 vaccines and that they generate antibody titers in people in order for vaccines to be considered for approval.
